Galderma achieved net sales of 4.082 B USD, up 8.5% year-on-year on a constant currency basis 1 in FY 2023, at the higher end of its 6-9% net sales growth 2023 FY guidance, and surpassed 4 B USD ...

PARIS — Swiss skin care company Galderma’s shares soared Friday, the first day of trading on the SIX Swiss Exchange in Zurich. The stock closed the day up 20.75 percent to 64 Swiss francs, or ...

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated ...

The boss of Swiss skincare group Galderma GALD 1.08 % increase; green up pointing triangle thinks treatments for what has been dubbed “Ozempic face” could give the company a lift.

Y lo hace confiando en una marca con más de 75 años de historia: Cetaphil ® de laboratorios Galderma, la marca experta para el ciudado de la piel sensible que tiene más relevancia que nunca en ...

In total, Galderma will present 30 abstracts at the congress, reinforcing its leadership and commitment to advancing dermatology for every skin story September 17, 2024 01:00 AM Eastern Daylight Time ...

Dermatology specialist Galderma is teaming up with the National Breast Cancer Foundation (NBCF) for Breast Cancer Awareness Month this October as it looks to deal with a forgotten element of ...

Dermatology company Galderma may be best known for its moisturizer Cetaphil — but it’s taking on a new marketing challenge by bringing attention to its atopic dermatitis drug Nemluvio. On Tuesday ...

Skin care company Galderma said on Thursday it had set the final price for its initial public offering (IPO) at 53 Swiss francs ($59.86) per share, at the top of its announced range, implying a ...

Galderma officially kicked off its latest campaign for Restylane injectables at New York City’s PrideFest on Sunday. Complementing the event's theme of “Unapologetically Us,” Galderma’s ...

Swiss dermatology company Galderma posted $3.8 billion in net sales during 2022, up 13.9% on 2021 on a constant currency basis, driven by growth in its injectable aesthetics and dermatological ...